Appropriate selection of biochemical targets is one of the most
important drivers of cost effectiveness in the discovery of new
medicines. Despite the many advances in genetics, genomics and
systems biology, 'validation' of a target is not achieved until
therapeutic efficacy is demonstrated by a drug candidate. Volume 46
of this series reviews the medicinal chemistry aimed at six diverse
targets from which important new medicines are emerging:
* HIV integrase (discovery of the first-in-class inhibitor drug
raltegravir)
* 11-beta-Hydroxysteroid dehydrogenase (new approach to
glucocorticoid regulation)
* Nicotinic a7 choline receptor (agonists and positive allosteric
modulators).
* Bradykinin receptor (new approach to pain therapy)
* Histone deacetylase (new drugs for cancer)
* 5-HT2c receptor modulators (various CNS indications)
*Presents the latest research in the field of drug discovery
*Publishes on an annual basis to bring you the most innovative
updates in medicinal chemistry
*Available as an online resource via ScienceDirect
General
Imprint: |
Elsevier Science Ltd
|
Country of origin: |
United Kingdom |
Series: |
Progress in Medicinal Chemistry |
Release date: |
April 2008 |
First published: |
May 2008 |
Series editors: |
G. Lawton
• David R. Witty
|
Dimensions: |
279 x 210 x 23mm (L x W x T) |
Format: |
Hardcover
|
Pages: |
420 |
Edition: |
47 Ed |
ISBN-13: |
978-0-444-53018-9 |
Categories: |
Books >
Medicine >
Other branches of medicine >
Pharmacology >
General
|
LSN: |
0-444-53018-5 |
Barcode: |
9780444530189 |
Is the information for this product incomplete, wrong or inappropriate?
Let us know about it.
Does this product have an incorrect or missing image?
Send us a new image.
Is this product missing categories?
Add more categories.
Review This Product
No reviews yet - be the first to create one!